v3.26.1
Segment Reporting - Summary of Significant Expense Categories and Consolidated Net Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting Information [Line Items]        
Revenue $ 10,131 $ 11,175 $ 20,992 $ 21,635
Operating costs and expenses:        
Clinical development, contract manufacturing and other third party costs 23,560 19,079 44,990 37,021
Employee costs 14,962 10,920 28,640 22,894
Facilities costs 2,790 2,968 5,623 6,326
Other operating costs 7,095 10,324 14,797 27,584
Other segment expenses 4,065 4,114 8,337 8,575
Total operating costs and expenses 52,472 47,405 102,387 102,400
Loss from operations (42,341) (36,230) (81,395) (80,765)
Non-operating income (expense):        
Non-cash interest expense on liabilities related to the sales of future royalties (7,206) (5,394) (15,148) (10,368)
Interest income 9,346 1,969 13,588 4,843
Other income (expense), net (100) 260 (436) 526
Total non-operating income (expense), net 2,040 (3,165) (1,996) (4,999)
Loss before provision for income taxes and equity method investment (40,301) (39,395) (83,391) (85,764)
Provision (benefit) for income taxes 2 (188) 66 (136)
Loss before equity method investment (40,303) (39,207) (83,457) (85,628)
Loss from equity method investment (319) (2,386) (2,069) (6,847)
Net loss (40,622) (41,593) (85,526) (92,475)
Rezpegaldesleukin (cytokine Treg stimulant)        
Operating costs and expenses:        
Clinical development, contract manufacturing and other third party costs 22,389 12,930 43,125 26,733
TNFR2 Program [Member]        
Operating costs and expenses:        
Clinical development, contract manufacturing and other third party costs 735 3,775 1,533 6,244
Discovery Research and Other Programs        
Operating costs and expenses:        
Clinical development, contract manufacturing and other third party costs $ 436 $ 2,374 $ 332 $ 4,044